Search

Your search keyword '"Canary PASS Investigators"' showing total 7 results
Start Over Descriptor "Canary PASS Investigators"
7 results on '"Canary PASS Investigators"'

1. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

Author

Huynh-Le, Minh-Phuong, Karunamuni, Roshan, Fan, Chun Chieh, Asona, Lui, Thompson, Wesley K, Martinez, Maria Elena, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth R, Lophatananon, Artitaya, Schleutker, Johanna, Pashayan, Nora, Batra, Jyotsna, Grönberg, Henrik, Neal, David E, Nordestgaard, Børge G, Tangen, Catherine M, MacInnis, Robert J, Wolk, Alicja, Albanes, Demetrius, Haiman, Christopher A, Travis, Ruth C, Blot, William J, Stanford, Janet L, Mucci, Lorelei A, West, Catharine ML, Nielsen, Sune F, Kibel, Adam S, Cussenot, Olivier, Berndt, Sonja I, Koutros, Stella, Sørensen, Karina Dalsgaard, Cybulski, Cezary, Grindedal, Eli Marie, Menegaux, Florence, Park, Jong Y, Ingles, Sue A, Maier, Christiane, Hamilton, Robert J, Rosenstein, Barry S, Lu, Yong-Jie, Watya, Stephen, Vega, Ana, Kogevinas, Manolis, Wiklund, Fredrik, Penney, Kathryn L, Huff, Chad D, Teixeira, Manuel R, Multigner, Luc, Leach, Robin J, Brenner, Hermann, John, Esther M, Kaneva, Radka, Logothetis, Christopher J, Neuhausen, Susan L, De Ruyck, Kim, Ost, Piet, Razack, Azad, Newcomb, Lisa F, Fowke, Jay H, Gamulin, Marija, Abraham, Aswin, Claessens, Frank, Castelao, Jose Esteban, Townsend, Paul A, Crawford, Dana C, Petrovics, Gyorgy, van Schaik, Ron HN, Parent, Marie-Élise, Hu, Jennifer J, Zheng, Wei, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, and Seibert, Tyler M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Prostate Cancer, Cancer, Urologic Diseases, Prevention, Genetics, Good Health and Well Being, Male, Humans, Prostate-Specific Antigen, Prostatic Neoplasms, Early Detection of Cancer, Polymorphism, Single Nucleotide, Risk Factors, Risk Assessment, Genetic Predisposition to Disease, UKGPCS collaborators, APCB, NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium, Urology & Nephrology, Clinical sciences, Oncology and carcinogenesis
Abstract

BackgroundProstate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets.MethodsIn total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry-the Cohort of Swedish Men (COSM) and the ProtecT study. Hazard ratios (HRs) were estimated to compare men with high versus low PHS for association with clinically significant, with any, and with fatal prostate cancer. The impact of genetic risk stratification on the positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was also measured.ResultsThe final model (PHS290) had 290 SNPs with non-zero coefficients. Comparing, for example, the highest and lowest quintiles of PHS290, the hazard ratios (HRs) for clinically significant prostate cancer were 13.73 [95% CI: 12.43-15.16] in ProtecT, 7.07 [6.58-7.60] in African ancestry, 10.31 [9.58-11.11] in Asian ancestry, and 11.18 [10.34-12.09] in COSM. Similar results were seen for association with any and fatal prostate cancer. Without PHS stratification, the PPV of PSA testing for clinically significant prostate cancer in ProtecT was 0.12 (0.11-0.14). For the top 20% and top 5% of PHS290, the PPV of PSA testing was 0.19 (0.15-0.22) and 0.26 (0.19-0.33), respectively.ConclusionsWe demonstrate better genetic risk stratification for clinically significant prostate cancer than prior versions of PHS in multi-ancestry datasets. This is promising for implementing precision-medicine approaches to prostate cancer screening decisions in diverse populations.

Published
2022

2. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer.

Author

Karunamuni, Roshan A, Huynh-Le, Minh-Phuong, Fan, Chun C, Thompson, Wesley, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth, Lophatananon, Artitaya, UKGPCS collaborators, Schleutker, Johanna, Pashayan, Nora, Batra, Jyotsna, APCB BioResource (Australian Prostate Cancer BioResource), Grönberg, Henrik, Walsh, Eleanor I, Turner, Emma L, Lane, Athene, Martin, Richard M, Neal, David E, Donovan, Jenny L, Hamdy, Freddie C, Nordestgaard, Børge G, Tangen, Catherine M, MacInnis, Robert J, Wolk, Alicja, Albanes, Demetrius, Haiman, Christopher A, Travis, Ruth C, Stanford, Janet L, Mucci, Lorelei A, West, Catharine ML, Nielsen, Sune F, Kibel, Adam S, Wiklund, Fredrik, Cussenot, Olivier, Berndt, Sonja I, Koutros, Stella, Sørensen, Karina Dalsgaard, Cybulski, Cezary, Grindedal, Eli Marie, Park, Jong Y, Ingles, Sue A, Maier, Christiane, Hamilton, Robert J, Rosenstein, Barry S, Vega, Ana, IMPACT Study Steering Committee and Collaborators, Kogevinas, Manolis, Penney, Kathryn L, Teixeira, Manuel R, Brenner, Hermann, John, Esther M, Kaneva, Radka, Logothetis, Christopher J, Neuhausen, Susan L, Razack, Azad, Newcomb, Lisa F, Canary PASS Investigators, Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Townsend, Paul A, Roobol, Monique J, Zheng, Wei, Profile Study Steering Committee, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, Seibert, Tyler M, and PRACTICAL Consortium

Subjects
UKGPCS collaborators, APCB BioResource, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium, Prevention, Urologic Diseases, Cancer, Prostate Cancer, Aging, Urology & Nephrology, Oncology and Carcinogenesis
Abstract

BackgroundPolygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).Materials and method180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy.Results166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer.ConclusionsIncorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.

Published
2021

3. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations.

Author

Huynh-Le, Minh-Phuong, Fan, Chun Chieh, Karunamuni, Roshan, Thompson, Wesley K, Martinez, Maria Elena, Eeles, Rosalind A, Kote-Jarai, Zsofia, Muir, Kenneth, Schleutker, Johanna, Pashayan, Nora, Batra, Jyotsna, Grönberg, Henrik, Neal, David E, Donovan, Jenny L, Hamdy, Freddie C, Martin, Richard M, Nielsen, Sune F, Nordestgaard, Børge G, Wiklund, Fredrik, Tangen, Catherine M, Giles, Graham G, Wolk, Alicja, Albanes, Demetrius, Travis, Ruth C, Blot, William J, Zheng, Wei, Sanderson, Maureen, Stanford, Janet L, Mucci, Lorelei A, West, Catharine ML, Kibel, Adam S, Cussenot, Olivier, Berndt, Sonja I, Koutros, Stella, Sørensen, Karina Dalsgaard, Cybulski, Cezary, Grindedal, Eli Marie, Menegaux, Florence, Khaw, Kay-Tee, Park, Jong Y, Ingles, Sue A, Maier, Christiane, Hamilton, Robert J, Thibodeau, Stephen N, Rosenstein, Barry S, Lu, Yong-Jie, Watya, Stephen, Vega, Ana, Kogevinas, Manolis, Penney, Kathryn L, Huff, Chad, Teixeira, Manuel R, Multigner, Luc, Leach, Robin J, Cannon-Albright, Lisa, Brenner, Hermann, John, Esther M, Kaneva, Radka, Logothetis, Christopher J, Neuhausen, Susan L, De Ruyck, Kim, Pandha, Hardev, Razack, Azad, Newcomb, Lisa F, Fowke, Jay H, Gamulin, Marija, Usmani, Nawaid, Claessens, Frank, Gago-Dominguez, Manuela, Townsend, Paul A, Bush, William S, Roobol, Monique J, Parent, Marie-Élise, Hu, Jennifer J, Mills, Ian G, Andreassen, Ole A, Dale, Anders M, Seibert, Tyler M, UKGPCS collaborators, APCB (Australian Prostate Cancer BioResource), NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, and PRACTICAL Consortium

Subjects
UKGPCS collaborators, APCB, NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium, Humans, Prostatic Neoplasms, Neoplasm Invasiveness, Multivariate Analysis, Multifactorial Inheritance, Aged, Middle Aged, Ethnic Groups, Male, Self Report, Aging, Urologic Diseases, Cancer, Prostate Cancer
Abstract

Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in Europeans. Here, we evaluate performance of PHS2 (PHS1, adapted for OncoArray) in a multi-ethnic dataset of 80,491 men (49,916 cases, 30,575 controls). PHS2 is associated with age at diagnosis of any and aggressive (Gleason score ≥ 7, stage T3-T4, PSA ≥ 10 ng/mL, or nodal/distant metastasis) cancer and prostate-cancer-specific death. Associations with cancer are significant within European (n = 71,856), Asian (n = 2,382), and African (n = 6,253) genetic ancestries (p

Published
2021

4. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Author

Schumacher, Fredrick R, Al Olama, Ali Amin, Berndt, Sonja I, Benlloch, Sara, Ahmed, Mahbubl, Saunders, Edward J, Dadaev, Tokhir, Leongamornlert, Daniel, Anokian, Ezequiel, Cieza-Borrella, Clara, Goh, Chee, Brook, Mark N, Sheng, Xin, Fachal, Laura, Dennis, Joe, Tyrer, Jonathan, Muir, Kenneth, Lophatananon, Artitaya, Stevens, Victoria L, Gapstur, Susan M, Carter, Brian D, Tangen, Catherine M, Goodman, Phyllis J, Thompson, Ian M, Batra, Jyotsna, Chambers, Suzanne, Moya, Leire, Clements, Judith, Horvath, Lisa, Tilley, Wayne, Risbridger, Gail P, Gronberg, Henrik, Aly, Markus, Nordström, Tobias, Pharoah, Paul, Pashayan, Nora, Schleutker, Johanna, Tammela, Teuvo LJ, Sipeky, Csilla, Auvinen, Anssi, Albanes, Demetrius, Weinstein, Stephanie, Wolk, Alicja, Håkansson, Niclas, West, Catharine ML, Dunning, Alison M, Burnet, Neil, Mucci, Lorelei A, Giovannucci, Edward, Andriole, Gerald L, Cussenot, Olivier, Cancel-Tassin, Géraldine, Koutros, Stella, Beane Freeman, Laura E, Sorensen, Karina Dalsgaard, Orntoft, Torben Falck, Borre, Michael, Maehle, Lovise, Grindedal, Eli Marie, Neal, David E, Donovan, Jenny L, Hamdy, Freddie C, Martin, Richard M, Travis, Ruth C, Key, Tim J, Hamilton, Robert J, Fleshner, Neil E, Finelli, Antonio, Ingles, Sue Ann, Stern, Mariana C, Rosenstein, Barry S, Kerns, Sarah L, Ostrer, Harry, Lu, Yong-Jie, Zhang, Hong-Wei, Feng, Ninghan, Mao, Xueying, Guo, Xin, Wang, Guomin, Sun, Zan, Giles, Graham G, Southey, Melissa C, MacInnis, Robert J, FitzGerald, Liesel M, Kibel, Adam S, Drake, Bettina F, Vega, Ana, Gómez-Caamaño, Antonio, Szulkin, Robert, Eklund, Martin, Kogevinas, Manolis, Llorca, Javier, Castaño-Vinyals, Gemma, Penney, Kathryn L, Stampfer, Meir, Park, Jong Y, Sellers, Thomas A, Lin, Hui-Yi, Stanford, Janet L, and Cybulski, Cezary

Subjects
Cancer, Aging, Prostate Cancer, Genetics, Urologic Diseases, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Case-Control Studies, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Male, Polymorphism, Single Nucleotide, Prostatic Neoplasms, Risk, Profile Study, Australian Prostate Cancer BioResource, IMPACT Study, Canary PASS Investigators, Breast and Prostate Cancer Cohort Consortium, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Cancer of the Prostate in Sweden, Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci, Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Biological Sciences, Medical and Health Sciences, Developmental Biology
Abstract

Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10-9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55-2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04-6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1.

Published
2018

5. Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Author

Newcomb, Lisa F, Thompson, Ian M, Boyer, Hilary D, Brooks, James D, Carroll, Peter R, Cooperberg, Matthew R, Dash, Atreya, Ellis, William J, Fazli, Ladan, Feng, Ziding, Gleave, Martin E, Kunju, Priya, Lance, Raymond S, McKenney, Jesse K, Meng, Maxwell V, Nicolas, Marlo M, Sanda, Martin G, Simko, Jeffry, So, Alan, Tretiakova, Maria S, Troyer, Dean A, True, Lawrence D, Vakar-Lopez, Funda, Virgin, Jeff, Wagner, Andrew A, Wei, John T, Zheng, Yingye, Nelson, Peter S, Lin, Daniel W, and Canary PASS Investigators

Subjects
Canary PASS Investigators, Humans, Prostatic Neoplasms, Biopsy, Treatment Outcome, Prostatectomy, Tumor Burden, Population Surveillance, Risk Factors, Prospective Studies, Aged, Middle Aged, Male, Watchful Waiting, Neoplasm Grading, Biomarkers, Tumor, prospective studies, prostatic neoplasms, watchful waiting, Clinical Research, Urologic Diseases, Prostate Cancer, Cancer, Prevention, Aging, Patient Safety, Clinical Sciences, Urology & Nephrology
Abstract

PurposeActive surveillance represents a strategy to address the overtreatment of prostate cancer, yet uncertainty regarding individual patient outcomes remains a concern. We evaluated outcomes in a prospective multicenter study of active surveillance.Materials and methodsWe studied 905 men in the prospective Canary PASS enrolled between 2008 and 2013. We collected clinical data at study entry and at prespecified intervals, and determined associations with adverse reclassification, defined as increased Gleason grade or greater cancer volume on followup biopsy. We also evaluated the relationships of clinical parameters with pathology findings in participants who underwent surgery after a period of active surveillance.ResultsAt a median followup of 28 months 24% of participants experienced adverse reclassification, of whom 53% underwent treatment while 31% continued on active surveillance. Overall 19% of participants received treatment, 68% with adverse reclassification, while 32% opted for treatment without disease reclassification. In multivariate Cox proportional hazards modeling the percent of biopsy cores with cancer, body mass index and prostate specific antigen density were associated with adverse reclassification (p=0.01, 0.04, 0.04, respectively). Of 103 participants subsequently treated with radical prostatectomy 34% had adverse pathology, defined as primary pattern 4-5 or nonorgan confined disease, including 2 with positive lymph nodes, with no significant relationship between risk category at diagnosis and findings at surgery (p=0.76).ConclusionsMost men remain on active surveillance at 5 years without adverse reclassification or adverse pathology at surgery. However, clinical factors had only a modest association with disease reclassification, supporting the need for approaches that improve the prediction of this outcome.

Published
2016

6. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

Author

Florence Menegaux, William J. Blot, Henrik Grönberg, Luc Multigner, Sune F. Nielsen, Stella Koutros, Frank Claessens, Manuela Gago-Dominguez, Kathryn L. Penney, Tyler M. Seibert, Cezary Cybulski, Jennifer J. Hu, Hermann Brenner, Radka Kaneva, Sue A. Ingles, Catherine M. Tangen, Ian G. Mills, Janet L. Stanford, Karina Dalsgaard Sørensen, Ruth C. Travis, Marie-Élise Parent, Monique J. Roobol, Nora Pashayan, Jyotsna Batra, Maria Elena Martinez, Anders M. Dale, Wei Zheng, Kay-Tee Khaw, Chad D. Huff, Chun Chieh Fan, Paul A. Townsend, Kim De Ruyck, Yong-Jie Lu, Eli Marie Grindedal, Hardev Pandha, Sonja I. Berndt, Susan L. Neuhausen, Alicja Wolk, Apcb, Wesley K. Thompson, Maureen Sanderson, Demetrius Albanes, Stephen N. Thibodeau, Christiane Maier, Kenneth Muir, Robin J. Leach, Børge G. Nordestgaard, Ole A. Andreassen, Fredrik Wiklund, Graham G. Giles, Zsofia Kote-Jarai, Catharine M L West, Minh-Phuong Huynh-Le, Manolis Kogevinas, Manuel R. Teixeira, Jong Y. Park, Johanna Schleutker, Marija Gamulin, Freddie C. Hamdy, William S. Bush, Barry S. Rosenstein, Stephen Watya, Roshan Karunamuni, Richard M. Martin, Nc-La PCaP Investigators, Ana Vega, Adam S. Kibel, Lisa A. Cannon-Albright, Azad Hassan Abdul Razack, Esther M. John, Christopher J. Logothetis, Jay H. Fowke, Nawaid Usmani, David E. Neal, Canary Pass Investigators, Rosalind A. Eeles, Robert J. Hamilton, Lisa F. Newcomb, Jenny L Donovan, Olivier Cussenot, Lorelei A. Mucci, University of California [San Diego] (UC San Diego), University of California, The institute of cancer research [London], University of Manchester [Manchester], University of Turku, Centre for Cancer Genetic Epidemiology [Cambridge], Department of Oncology-University of Cambridge [UK] (CAM), University College of London [London] (UCL), Centre de Recherche pour les Pathologies Prostatiques [Paris] (CeRePP), Sorbonne Université (SU), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), This study was funded in part by a grant from the United States National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (#K08EB026503), United States Department of Defense (#W81XWH-13-1-0391), University of California CRCC C21CR2060, the Research Council of Norway (#223273), K.G. Jebsen Stiftelsen, and South East Norway Health Authority. RM Martin is supported in part by the National Institute for Health Research Bristol Biomedical Research Centre. The CAP trial is funded by Cancer Research UK and the UK Department of Health (C11043/A4286, C18281/A8145, C18281/A11326, C18281/A15064, and C18281/A24432). R.M. Martin was supported by a Cancer Research UK (C18281/A19169) program grant (the Integrative Cancer Epidemiology Programme). Funding for the PRACTICAL consortium member studies is detailed in the Supplementary Information., University of California (UC), University of Cambridge [UK] (CAM)-Department of Oncology, Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Huynh-Le, Minh-Phuong [0000-0002-5025-4709], Fan, Chun Chieh [0000-0001-9437-2128], Eeles, Rosalind A [0000-0002-3698-6241], Muir, Kenneth [0000-0001-6429-988X], Schleutker, Johanna [0000-0002-1863-0305], Pashayan, Nora [0000-0003-0843-2468], Batra, Jyotsna [0000-0003-4646-6247], Grönberg, Henrik [0000-0002-1073-2753], Martin, Richard M [0000-0002-7992-7719], Nordestgaard, Børge G [0000-0002-1954-7220], Wiklund, Fredrik [0000-0002-4623-0544], Giles, Graham G [0000-0003-4946-9099], Wolk, Alicja [0000-0001-7387-6845], Travis, Ruth C [0000-0002-9571-0763], Zheng, Wei [0000-0003-1226-070X], West, Catharine ML [0000-0002-0839-3449], Sørensen, Karina Dalsgaard [0000-0002-4902-5490], Park, Jong Y [0000-0002-6384-6447], Vega, Ana [0000-0002-7416-5137], Teixeira, Manuel R [0000-0002-4896-5982], Multigner, Luc [0000-0003-3205-8568], Cannon-Albright, Lisa [0000-0003-2602-3668], Gamulin, Marija [0000-0003-2431-7910], Bush, William S [0000-0002-9729-6519], Roobol, Monique J [0000-0001-6967-1708], Andreassen, Ole A [0000-0002-4461-3568], Seibert, Tyler M [0000-0002-4089-7399], Apollo - University of Cambridge Repository, and Clinical Chemistry

Subjects
0301 basic medicine, Oncology, Male, Multifactorial Inheritance, Aging, Multivariate analysis, Ethnic Groups/genetics, General Physics and Astronomy, UKGPCS collaborators, Prostate cancer, 0302 clinical medicine, Urologi och njurmedicin, Ethnicity, risk factors, PRACTICAL Consortium, genetics, Stage (cooking), AgedEthnic Groups / genetics, Cancer, Multidisciplinary, Manchester Cancer Research Centre, Prostatic Neoplasms/genetics, Prostate Cancer, Hazard ratio, APCB, Middle Aged, Hazard, Health equity, 3. Good health, Multidisciplinary Sciences, 030220 oncology & carcinogenesis, Science & Technology - Other Topics, polygenic hazard score (PHS1), prostate cancer, ICEP, Medical Genetics, Urologic Diseases, medicine.medical_specialty, hazard, precision medicine, Science, Prostatic Neoplasms / genetics, [SDV.CAN]Life Sciences [q-bio]/Cancer, Ethnic Groups, survival, General Biochemistry, Genetics and Molecular Biology, Article, 03 medical and health sciences, Medical research, SDG 3 - Good Health and Well-being, Internal medicine, NC-LA PCaP Investigators, Genetic model, medicine, Urology and Nephrology, Humans, Neoplasm Invasiveness, Multifactorial Inheritance/genetics, Medicinsk genetik, Aged, Canary PASS Investigators, Science & Technology, IMPACT Study Steering Committee and Collaborators, business.industry, Profile Study Steering Committee, ResearchInstitutes_Networks_Beacons/mcrc, Prostatic Neoplasms, General Chemistry, medicine.disease, Multifactorial Inheritance / genetics, 030104 developmental biology, Multivariate Analysis, Self Report, business, Biomarkers
Abstract

Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in Europeans. Here, we evaluate performance of PHS2 (PHS1, adapted for OncoArray) in a multi-ethnic dataset of 80,491 men (49,916 cases, 30,575 controls). PHS2 is associated with age at diagnosis of any and aggressive (Gleason score ≥ 7, stage T3-T4, PSA ≥ 10 ng/mL, or nodal/distant metastasis) cancer and prostate-cancer-specific death. Associations with cancer are significant within European (n = 71,856), Asian (n = 2,382), and African (n = 6,253) genetic ancestries (p, A polygenic hazard score (PHS1) improves prostate cancer screening accuracy in European patients. Here, the authors test the performance of a version compatible with OncoArray genotypes (PHS2) in a multi-ethnic dataset and find that it risk-stratifies men for any, aggressive, and fatal prostate cancer.

Published
2021
Full Text
View/download PDF

7. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

Author

Rosalind A. Eeles, Karina Dalsgaard Sørensen, Torben F. Ørntoft, Jeri Kim, Wayne D. Tilley, Ruth C. Travis, Lorelei A. Mucci, Jenny L Donovan, Kay-Tee Khaw, Edward Giovannucci, Christopher I. Amos, Soo Hwang Teo, Claire Aukim-Hastie, Gerald L. Andriole, Linda Steele, Martin Eklund, Guomin Wang, Michael Borre, Antonio Finelli, Liesel M. FitzGerald, Thérèse Truong, Robert N. Hoover, Sandeep Singhal, Radka Kaneva, Frank Claessens, Robert Szulkin, Javier Llorca, Dominika Wokołorczyk, Esther M. John, Daniel J. Schaid, Jyotsna Batra, Kathryn L. Penney, Børge G. Nordestgaard, Catharine M L West, Hermann Brenner, Sue A. Ingles, Markus Aly, Jonathan Tyrer, Thomas J. Schnoeller, Xin Guo, Peter Iversen, Olivier Cussenot, Laurence N. Kolonel, Henrik Grönberg, Ninghan Feng, Geraldine Cancel-Tassin, Christiane Maier, David E. Neal, Marija Gamulin, Ezequiel Anokian, Christopher J. Logothetis, Shannon K. McDonnell, Lovise Maehle, Anssi Auvinen, Antonio Gómez-Caamaño, Tomislav Kuliš, Manuel Luedeke, Teuvo L.J. Tammela, Brian D. Carter, Zan Sun, Jong Y. Park, Nawaid Usmani, Ian M. Thompson, Zuxi Cui, Johanna Schleutker, Bernd Holleczek, Davor Lessel, Katarina Cuk, Eli Marie Grindedal, Milan S. Geybels, Yuan Chun Ding, Phyllis J. Goodman, Jing Ma, Paul A. Townsend, Edward J. Saunders, Melissa C. Southey, Graham G. Giles, Robert J. Hamilton, Laura Fachal, Mitchell J. Machiela, Demetrius Albanes, Gert De Meerleer, Paula Paulo, Agnieszka Michael, Yves Akoli Koudou, Janet L. Stanford, Kim De Ruyck, Thomas Van den Broeck, Tokhir Dadaev, Clara Cieza-Borrella, Sonja I. Berndt, Artitaya Lophatananon, Brian E. Henderson, Niclas Håkansson, Christopher A. Haiman, Florence Menegaux, Xueying Mao, Jan Lubinski, Elio Riboli, Paul D.P. Pharoah, David J. Hunter, Loic Le Marchand, Stephen N. Thibodeau, Fredrik Wiklund, Tobias Nordström, Thomas A. Sellers, Chee Goh, Elaine A. Ostrander, Sune F. Nielsen, Neil E. Fleshner, Neil G. Burnet, Rasmus Bisbjerg, Manuela Gago Dominguez, Csilla Sipeky, Maria Elena Martinez, Susan L. Neuhausen, Stephen J. Chanock, Hui Yi Lin, Laura E. Beane Freeman, A. Siddiq, Alicja Wolk, Gemma Castaño-Vinyals, Lisa F. Newcomb, Catherine M. Tangen, Ana Vega, Peter Kraft, Chavdar Slavov, Daniel Leongamornlert, Lisa A. Cannon-Albright, Stella Koutros, Manuel R. Teixeira, Susan M. Gapstur, Federico Canzian, Sara Lindström, Maren Weischer, Bettina F. Drake, Lisa G. Horvath, Daniel W. Lin, Jose Esteban Castelao, Yong-Jie Lu, Xin Sheng, Vanio Mitev, Ron H.N. van Schaik, Monique J. Roobol, Zsofia Kote-Jarai, Leire Moya, Alison M. Dunning, Mahbubl Ahmed, Kenneth Muir, Douglas F. Easton, Suzanne K. Chambers, Hongwei Zhang, Jianfeng Xu, Jasmine Lim, Meir J. Stampfer, Guido Jenster, Ali Amin Al Olama, Victoria L. Stevens, Sara Benlloch, Mark N. Brook, Azad Hassan Abdul Razack, Marta Cardoso, Matthew Parliament, Gail P. Risbridger, Samantha E.T. Larkin, Fredrick R. Schumacher, Martin Andreas Røder, Harry Ostrer, Judith A. Clements, Manolis Kogevinas, Barry S. Rosenstein, Steven Joniau, Richard M. Martin, Constance Turman, Mariana C. Stern, Joe Dennis, David V. Conti, Sarah L. Kerns, Adam S. Kibel, Robert J. MacInnis, Stephanie J. Weinstein, Freddie C. Hamdy, Cezary Cybulski, Nora Pashayan, Timothy J. Key, Hardev Pandha, Piet Ost, Urology, Clinical Chemistry, Imperial College Trust, Schumacher, Fredrick R [0000-0002-3073-7463], and Apollo - University of Cambridge Repository

Subjects
0301 basic medicine, Oncology, Male, PREDICTION, Cancer of the Prostate in Sweden (CAPS), Genome-wide association study, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, VARIANTS, Australian Prostate Cancer BioResource (APCB), urologic and male genital diseases, DISEASE, FAMILY-HISTORY, PATHWAY, Prostate cancer, Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS), 11 Medical and Health Sciences, Genetics & Heredity, RISK, education.field_of_study, Profile Study, IMPACT Study, 3. Good health, prostate cancer (PrCa)-susceptibility loci, Centre for Surgical Research, BIOLOGICAL PATHWAYS, ICEP, Life Sciences & Biomedicine, Medical Genetics, Risk, medicine.medical_specialty, Genotype, Population, Biology, Polymorphism, Single Nucleotide, 03 medical and health sciences, MULTIPLE LOCI, Breast and Prostate Cancer Cohort Consortium (BPC3), SDG 3 - Good Health and Well-being, Internal medicine, Genetic model, Genetics, medicine, Humans, Genetic Predisposition to Disease, GENOME-WIDE ASSOCIATION, education, Genotyping, METAANALYSIS, Medicinsk genetik, Genetic association, Canary PASS Investigators, Science & Technology, IDENTIFICATION, CONSORTIUM, Case-control study, Prostatic Neoplasms, 06 Biological Sciences, medicine.disease, GENE, Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, 030104 developmental biology, Genetic Loci, Relative risk, Case-Control Studies, genotype, humans, male, Developmental Biology, Genome-Wide Association Study
Abstract

Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10-8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10-9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10-9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55-2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04-6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa 1 .

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results